Share

|

|

|

Blood immunoassay shows high diagnostic accuracy for Alzheimer’s disease pathology

Elderly woman in hospital room with doctor and nurse. Neurologist holding anatomical model of human brain, conceptual image

A commercially available plasma phosphorylated (p)-tau217 immunoassay outperforms other biomarkers in accurately identifying biological Alzheimer’s disease, suggest findings from a study across three observational cohorts.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Cerliponase alfa treatment shows extended efficacy for CLN2 disease

Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Young age reduces MS disability but does not fully protect against it

Progression of multiple sclerosis in the absence of relapses can occur at any age, although it is less common in children than adults with the condition, suggests research.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Cortical gyrification a possible early biomarker for PD progression

Researchers have found reductions in cortical gyrifications in patients with newly diagnosed Parkinson’s disease that worsen over time and may therefore serve as a potential biomarker for disease progression.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Pathogenic variants have additive effect on ALS survival

Genetic variants that modify survival in amyotrophic lateral sclerosis (ALS) can act on their own or in unison, having an additive effect and significantly worsening a patient’s outcome, researchers report in the journal Neurology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

α-synuclein seed amplification potential for early Parkinson’s disease diagnosis

An assay for identifying the build-up of the misfolded α-synuclein protein in cerebrospinal fluid could enhance the detection of Parkinson’s disease in the early stages before the onset of motor symptoms, suggests research.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.